关注
RB Warren
RB Warren
University of manchester UK
在 manchester.ac.uk 的电子邮件经过验证
标题
引用次数
引用次数
年份
Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
A Strange, F Capon, CCA Spencer, J Knight, ME Weale, MH Allen, ...
Nature genetics 42 (11), 985, 2010
10252010
European consensus statement on phenotypes of pustular psoriasis
AA Navarini, AD Burden, F Capon, U Mrowietz, L Puig, S Köks, K Kingo, ...
Journal of the European Academy of Dermatology and Venereology 31 (11), 1792 …, 2017
4472017
Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists …
RB Warren, CH Smith, ZZN Yiu, DM Ashcroft, JNWN Barker, AD Burden, ...
Journal of Investigative Dermatology 135 (11), 2632-2640, 2015
4322015
Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis
EJ Samarasekera, JM Neilson, RB Warren, J Parnham, CH Smith
Journal of Investigative Dermatology 133 (10), 2340-2346, 2013
3232013
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017
CH Smith, ZK Jabbar‐Lopez, ZZ Yiu, T Bale, AD Burden, LC Coates, ...
British Journal of Dermatology 177 (3), 628-636, 2017
3062017
Psoriasis: is the impairment to a patient’s life cumulative?
AB Kimball, U Gieler, D Linder, F Sampogna, RB Warren, M Augustin
Journal of the European Academy of Dermatology and Venereology 24 (9), 989-1004, 2010
2782010
Bimekizumab versus secukinumab in plaque psoriasis
K Reich, RB Warren, M Lebwohl, M Gooderham, B Strober, RG Langley, ...
New England Journal of Medicine 385 (2), 142-152, 2021
2532021
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
M Jani, A Barton, RB Warren, CEM Griffiths, H Chinoy
Rheumatology 53 (2), 213-222, 2014
2502014
Identification of ZNF313 / RNF114 as a novel psoriasis susceptibility gene
F Capon, MJ Bijlmakers, N Wolf, M Quaranta, U Huffmeier, M Allen, ...
Human molecular genetics 17 (13), 1938-1945, 2008
2362008
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active …
K Reich, KA Papp, A Blauvelt, RG Langley, A Armstrong, RB Warren, ...
The Lancet 397 (10273), 487-498, 2021
2302021
Clinical and genetic differences between pustular psoriasis subtypes
S Twelves, A Mostafa, N Dand, E Burri, K Farkas, R Wilson, HL Cooper, ...
Journal of allergy and clinical immunology 143 (3), 1021-1026, 2019
2122019
Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis
J Bowes, A Budu-Aggrey, U Huffmeier, S Uebe, K Steel, HL Hebert, ...
Nature communications 6 (1), 6046, 2015
2072015
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo …
AW Armstrong, M Gooderham, RB Warren, KA Papp, B Strober, D Thaçi, ...
Journal of the American Academy of Dermatology 88 (1), 29-39, 2023
2022023
A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis
U Mrowietz, E De Jong, K Kragballe, R Langley, A Nast, L Puig, K Reich, ...
Journal of the European Academy of Dermatology and Venereology 28 (4), 438-453, 2014
1942014
Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)
LC Coates, T Aslam, F Al Balushi, AD Burden, E Burden‐The, ...
British Journal of Dermatology 168 (4), 802-807, 2013
1882013
Bimekizumab versus adalimumab in plaque psoriasis
RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, ...
New England Journal of Medicine 385 (2), 130-141, 2021
1782021
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
SK Mahil, N Dand, KJ Mason, ZZN Yiu, T Tsakok, F Meynell, B Coker, ...
Journal of allergy and clinical immunology 147 (1), 60-71, 2021
1732021
A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis
M Campa, B Mansouri, R Warren, A Menter
Dermatology and therapy 6, 1-12, 2016
1662016
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis
RB Warren, RL Smith, E Campalani, S Eyre, CH Smith, JNWN Barker, ...
Journal of Investigative Dermatology 128 (8), 1925-1929, 2008
1652008
Cumulative life course impairment in psoriasis: patient perception of disease‐related impairment throughout the life course
RB Warren, CE Kleyn, WP Gulliver
British Journal of Dermatology 164 (s1), 1-14, 2011
1622011
系统目前无法执行此操作,请稍后再试。
文章 1–20